Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma
Keywords:
Lymphoma, Oncogene proteins, Prognosis, Biological markers, Germinal centerAbstract
COntext and objective: Gene expression and immunohistochemical profiling of diffuse large B-cell lymphoma (DLBCL) have revealed important prognostic subgroups: germinal center B-cell-like (GCB-like) DLBCL and activated B cell-like (ABC-like) DLBCL. Although few reports on high-risk DLBCL are available, the prognosis for the GCB-like subgroup has been shown to be better than that of the ABC-like subgroup. The role of Bcl-2 as a predictor of survival in DLBCL cases is unclear and its expression varies between the two subgroups of DLBCL. In this study, we analyzed the frequency and prognostic impact of Bcl-2 protein expression in high-risk DLBCL cases. DESIGN AND SETTING: Retrospective cohort study among DLBCL patients treated at Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP). Methods: The prognostic impact of the expression of the proteins CD10, Bcl-6, MUM1 (multiple myeloma oncogene-1) and Bcl-2 on high-risk DLBCL cases was evaluated by means of immunohistochemistry. Seventy-three patients aged 18-60 years were evaluated for all these markers. Results: Twenty-four cases (32.9%) were GCB-like and 49 (67.1%) were ABC-like, with no difference regarding complete remission, disease-free survival or overall survival rates. Twenty-seven patients (37%) showed Bcl-2 expression, which was the only independent factor predicting a worse prognosis for overall survival according to multivariate analysis. Conclusion: Bcl-2 protein was expressed in 37% of the high-risk DLBCL patients, without any difference between the ABC-like DLBCL and GCB-like DLBCL cases.
Downloads
References
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-94.
Hallack Neto AE, Dorlhiac-Llacer P, Beitler B, Chamone DAF. Aplicação do índice prognóstico internacional em pacientes com linfoma difuso de grandes células B em uma instituição brasi- leira [The use of the international prognostic index in a Brazilian institution for patients suffering from diffuse large B-cell lymphoma]. Rev Bras Hematol Hemoter. 2005;27(1):27-30.
Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2(6): 418-27.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-11.
Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74.
Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28(4):464-70.
Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center ver- sus nongerminal center, determined by immunohistochemistry on tissue microarray,does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood. 2005;106(10):3383-5.
Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell–like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):961-8.
Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007.
Pereira J, Bellesso M, Pracchia LF, et al. Modified Magrath IVAC regimen as second-line the- rapy for relapsed or refractory aggressive non-Hodgkin’s lymphoma in developing countries: the experience of a single center in Brazil. Leuk Res. 2006;30(6):681-5.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunopero- xidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29(4):577-80.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor sub- set within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159-66.
Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistoche- mically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109(11):4930-5.
Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expres- sion in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107(11):4207-13.
van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-asso- ciated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(25):4135-42.
Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78-84.
Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression com- bined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood. 2002;99(4):1136-43.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-42.
Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2- associated resistance to chemotherapy in elderly patients with diffuse large B-cell lympho- ma (DLBCL). Blood. 2003;101(11):4279-84.
